Literature DB >> 9447482

Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor.

K M Grodecki1, M J Gains, R Baumal, D H Osmond, B Cotter, V E Valli, R M Jacobs.   

Abstract

X-linked hereditary nephritis (HN) in Samoyed dogs is a model for human HN (Alport's syndrome). Angiotensin converting enzyme (ACE) inhibitors have been shown to slow the progression of renal disease in animal models and human patients. To determine the effect of ACE inhibitor treatment on X-linked HN in Samoyed dogs, a group of affected and a group of normal males were each randomly divided into two subgroups, which were either treated with an ACE inhibitor or left untreated. ACE inhibitor treatment caused significant increases (P < 0.05) in plasma renin activity in normal and affected dogs, confirming its effectiveness, but did not lower systemic blood pressure. Three of four affected treated dogs had improved weight gains and, overall, treated dogs survived 1.36 times longer than affected untreated dogs (P < 0.05). ACE inhibitor treatment of affected dogs significantly delayed (P < 0.05) the onset of an increase in serum creatinine concentration, tended to delay the decline of glomerular filtration rate and effective renal plasma flow (ERPF), significantly improved (P < 0.05) the ERPF at 110-154 days of age, and significantly slowed (P < 0.01) the rate of increase of proteinuria. Affected treated dogs showed a significant (P < 0.05) transient reduction in glomerular basement membrane splitting. Thus, ACE inhibitor treatment of Samoyed dogs with X-linked HN produced beneficial effects with respect to renal function, renal structure, and survival.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447482     DOI: 10.1016/s0021-9975(97)80016-3

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  23 in total

1.  Alport syndrome: About time--treating children with Alport syndrome.

Authors:  Judy Savige
Journal:  Nat Rev Nephrol       Date:  2012-05-29       Impact factor: 28.314

Review 2.  Glomerular diseases: genetic causes and future therapeutics.

Authors:  Chih-Kang Chiang; Reiko Inagi
Journal:  Nat Rev Nephrol       Date:  2010-07-20       Impact factor: 28.314

Review 3.  Cell-matrix adhesion of podocytes in physiology and disease.

Authors:  Norman Sachs; Arnoud Sonnenberg
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

4.  Short-term effects of dietary supplementation with amino acids in dogs with proteinuric chronic kidney disease.

Authors:  Andrea Zatelli; Paola D'Ippolito; Xavier Roura; Eric Zini
Journal:  Can Vet J       Date:  2017-12       Impact factor: 1.008

5.  Cyclosporin therapy in patients with Alport syndrome.

Authors:  Marina Charbit; Marie-Claire Gubler; Michèle Dechaux; Marie-France Gagnadoux; Jean-Pierre Grünfeld; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

Review 6.  Alport syndrome--insights from basic and clinical research.

Authors:  Jenny Kruegel; Diana Rubel; Oliver Gross
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

7.  Diagnosis of Alport syndrome--search for proteomic biomarkers in body fluids.

Authors:  Michael Pohl; Karin Danz; Oliver Gross; Ulrike John; Johannes Urban; Ludwig Patzer; Sandra Habbig; Markus Feldkötter; Oliver Witzke; Mario Walther; Heidrun Rhode
Journal:  Pediatr Nephrol       Date:  2013-06-23       Impact factor: 3.714

8.  The effect of aldosterone blockade in patients with Alport syndrome.

Authors:  Hiroshi Kaito; Kandai Nozu; Kazumoto Iijima; Koichi Nakanishi; Kunihiko Yoshiya; Kyoko Kanda; Rafal Przybyslaw Krol; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2006-10-13       Impact factor: 3.714

Review 9.  Glomerular pathology in Alport syndrome: a molecular perspective.

Authors:  Dominic Cosgrove
Journal:  Pediatr Nephrol       Date:  2011-04-01       Impact factor: 3.714

Review 10.  Familial hematuria.

Authors:  Clifford E Kashtan
Journal:  Pediatr Nephrol       Date:  2007-10-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.